Current Challenges and Opportunities of Photodynamic Therapy against Cancer
Pharmaceutics · 18.01.2023 · 15 (2) · 330
DOI: 10.3390/pharmaceutics15020330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 18.01.2023. Verfasst von Ruben V Huis In 't Veld und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Leiden University Medical Centre (LUMC), 2333 ZA Leiden, Zuid-Holland, The Netherlands. Die Arbeit wurde bisher 155-mal zitiert (Crossref) und nennt 332 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Holland, Health-Holland.
Abstract (Originalsprache)
BACKGROUND: Photodynamic therapy (PDT) is an established, minimally invasive treatment for specific types of cancer. During PDT, reactive oxygen species (ROS) are generated that ultimately induce cell death and disruption of the tumor area. Moreover, PDT can result in damage to the tumor vasculature and induce the release and/or exposure of damage-associated molecular patterns (DAMPs) that may initiate an antitumor immune response. However, there are currently several challenges of PDT that limit its widespread application for certain indications in the clinic. METHODS: A literature study was conducted to comprehensively discuss these challenges and to identify opportunities for improvement. RESULTS: The most notable challenges of PDT and opportunities to improve them have been identified and discussed. CONCLUSIONS: The recent efforts to improve the current challenges of PDT are promising, most notably those that focus on enhancing immune responses initiated by the treatment. The application of these improvements has the potential to enhance the antitumor efficacy of PDT, thereby broadening its potential application in the clinic.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Leiden University Medical Centre (LUMC), 2333 ZA Leiden, Zuid-Holland, The Netherlands.
- Department of Radiology, Leiden University Medical Centre (LUMC), 2333 ZA Leiden, Zuid-Holland, The Netherlands.
- Department of Immunology, Leiden University Medical Centre (LUMC), 2333 ZA Leiden, Zuid-Holland, The Netherlands.
ORCID-Profile: Sen Ma, Martine J Jager
Förderung
- Health Holland
- Health-Holland
Zitieren
APA
Huis In 't Veld, R. V., Heuts, J., Ma, S., Cruz, L. J., Ossendorp, F. A., & Jager, M. J. (2023). Current Challenges and Opportunities of Photodynamic Therapy against Cancer. Pharmaceutics, 15(2), 330. https://doi.org/10.3390/pharmaceutics15020330
Vancouver
Huis In 't Veld RV, Heuts J, Ma S, Cruz LJ, Ossendorp FA, Jager MJ. Current Challenges and Opportunities of Photodynamic Therapy against Cancer. Pharmaceutics. 2023;15(2):330. doi:10.3390/pharmaceutics15020330
BibTeX
@article{HuisIntVeld2023,
author = {Huis In 't Veld, Ruben V and Heuts, Jeroen and Ma, Sen and Cruz, Luis J and Ossendorp, Ferry A and Jager, Martine J},
title = {Current Challenges and Opportunities of Photodynamic Therapy against Cancer},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {2},
pages = {330},
doi = {10.3390/pharmaceutics15020330}
}
EUVIMED